Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: First reported case

Basit Öğe Kaydı
dc.authorid0000-0003-1508-2822
dc.authorid0000-0001-6732-8068
dc.authorid0000-0003-4766-1861
dc.authorid0000-0002-9005-5587
dc.authorid0000-0002-2035-9462
dc.authorid0000-0001-9636-4113
dc.contributor.authorMutlu, Yaşa Gül
dc.contributor.authorYiğit Kaya, Süreyya
dc.contributor.authorMaral, Senem
dc.contributor.authorMelek, Elif
dc.contributor.authorBaşlar, Zafer
dc.contributor.authorKaynar, Leylagül
dc.contributor.authorSevindik, Ömür Gökmen
dc.date.accessioned2023-11-15T06:29:34Z
dc.date.available2023-11-15T06:29:34Z
dc.date.issued2023
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractCentral nervous system (CNS) involvement in multiple myeloma (MM) is a rare and challenging complication associated with poor prognosis and limited treatment options. Emerging T-cell directing therapies, such as bispecific antibodies (bsAbs) and chimeric antigen receptor T cells (CAR-T), have shown remarkable success in treating MM, but their efficacy in CNS involvement remains unclear. Elranatamab, a humanized bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3-expressing T cells, has demonstrated promising results in relapsed refractory MM. However, its efficacy in treating CNS-MM has not been reported. We present a case of a 37-year-old male MM patient with CNS involvement who has been successfully treated with Elranatamab.
dc.identifier.citationMutlu, Y. G., Yiğit Kaya, S., Maral, S., Melek, E., Başlar, Z., Kaynar, L. ... Sevindik, Ö. G. (2023). Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: First reported case. Frontiers in Immunology, 14. https://dx.doi.org/10.3389/fimmu.2023.1276295
dc.identifier.doi10.3389/fimmu.2023.1276295
dc.identifier.issn1664-3224
dc.identifier.pmid37901215
dc.identifier.scopus2-s2.0-85175253743
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://dx.doi.org/10.3389/fimmu.2023.1276295
dc.identifier.urihttps://hdl.handle.net/20.500.12511/11776
dc.identifier.volume14
dc.identifier.wos001088197200001en_US
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorMutlu, Yaşa Gül
dc.institutionauthorYiğit Kaya, Süreyya
dc.institutionauthorMaral, Senem
dc.institutionauthorMelek, Elif
dc.institutionauthorKaynar, Leylagül
dc.institutionauthorSevindik, Ömür Gökmen
dc.language.isoen
dc.publisherFrontiers Media SA
dc.relation.ispartofFrontiers in Immunologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsAttribution 4.0 International*
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subjectBCMA
dc.subjectBispecific Ab
dc.subjectCNS Involvement
dc.subjectElranatamab
dc.subjectMultiple Myeloma
dc.titleRelapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: First reported case
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Yasa-Mutlu-2023.pdf
Boyut:
1.92 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu